Rezvilutamide

• CAT Number: I035530
• CAS Number: 1572045-62-5
• Molecular Formula: C22H20F3N3O4S
• Molecular Weight: 479.47
• Purity: 98%
• Synonyms: Rezvilutamide
• Target: Androgen Receptor
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20℃ for long term (months to years).
• IUPAC Name: 4-(3-{4-[(2S)-2,3-dihydroxypropoxy]phenyl}-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl)-2 (trifluoromethyl)benzonitrileantiandrogen
• InChI: InChI=1S/C22H20F3N3O4S/c1-21(2)19(31)27(15-4-3-13(10-26)18(9-15)22(23,24)25)20(33)28(21)14-5-7-17(8-6-14)32-12-16(30)11-29/h3-9,16,29-30H,11-12H2,1-2H3/t16-/m0/s1
• InChIKey: KRBMOYIWQCZVHA-INIZCTEOSA-N
• SMILES: N#CC1=CC=C(N(C(N(C2=CC=C(OC[C@@H](O)CO)C=C2)C3(C)C)=S)C3=O)C=C1C(F)(F)F

Rezvilutamide(CAT: I035530) is a next-generation nonsteroidal androgen receptor (AR) antagonist that binds to and inhibits AR signaling, a critical driver in the progression of prostate cancer. By effectively blocking androgen-induced transcriptional activity, it disrupts cancer cell proliferation and survival, offering potential in the management of castration-resistant prostate cancer (CRPC). Rezvilutamide’s high specificity and efficacy make it an essential compound for research into AR-targeted therapies and overcoming resistance in advanced prostate cancer. It is a valuable tool for exploring therapeutic strategies in oncology, particularly within the realm of hormone-driven malignancies.